Stocks Health care LPCN
NASDAQ · Health careLipocine Inc. (LPCN)
Lipocine Inc. brought in $1.6M of revenue over the twelve months to June 30, 2026. It posted a net loss of $11.9M. At June 30, 2026 it held $5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
Key facts about Lipocine Inc.
- Net worth
- Lipocine Inc. has a market value (market cap) of $13M at the latest share price, and shareholders' equity of $21.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2M (-82.3% year on year), with a net loss of $9.6M. Over the 12 months to June 30, 2026: revenue $1.6M, net loss $11.9M.
- Cash flow
- In fiscal 2025 operations used $9.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 4, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Lipocine Inc.'s next report was expected around October 16, 2026 and is not on file with the SEC yet.
What Lipocine Inc. does
Lipocine Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LPCN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2M | -$9.6M | -$1.69 | n/a |
| 2024 | $11.2M | $8.4K | n/a | -$1.3M |
| 2023 | -$2.9M | -$16.4M | -$3.14 | -$11.9M |
| 2022 | $500K | -$10.8M | -$2.15 | -$12.1M |
| 2021 | $16.1M | -$634.4K | -$0.17 | -$4.4M |
| 2020 | $0 | -$21M | -$6.28 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LPCN ranks in Health care
Latest SEC filings
What Lipocine Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 16, 2026Other event 8-K
- September 14, 2026Other event 8-K
- September 11, 2026Other event 8-K
- September 10, 2026Other event 8-K
- August 21, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 69% to $190.1K versus the same quarter last year; diluted EPS -$0.32 versus -$0.41.
- August 3, 2026
- June 12, 2026Other event 8-K
Insider trades
What the people running Lipocine Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $82.2K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 30, 2026 | Higuchi John W.Director | Bought | 15,970 | $35.6K |
| September 29, 2026 | Higuchi John W.Director | Bought | 9,037 | $19.4K |
| September 28, 2026 | Higuchi John W.Director | Bought | 12,561 | $27.1K |
| April 7, 2026 | Higuchi John W.Director | Bought | 40,000 | $81.2K |
| April 6, 2026 | Patel Mahesh V.Chief Executive Officer, Director | Bought | 25,000 | $50.7K |
| April 6, 2026 | Higuchi John W.Director | Bought | 123,000 | $252.1K |
| April 2, 2026 | Patel Mahesh V.Chief Executive Officer, Director | Bought | 25,000 | $50.5K |
Who owns LPCN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Squadron Master Fund LP13G, passive with 3 related filers | 9.8% | August 14, 2026 |
| Ikarian Capital, LLC13G, passive with 1 related filers | 6.3% | May 15, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 402,044 shares in total, about $635.2K at the last price.
| Holder | Shares |
|---|---|
| Higuchi John W.Director | 241,365 |
| Patel Mahesh V.Chief Executive Officer, Director | 160,679 |
Questions about LPCN
What does Lipocine Inc. do?
Lipocine Inc. is a company in the Health care sector, listed on NASDAQ as LPCN. Its shares trade on NASDAQ under the ticker LPCN.
What is Lipocine Inc.'s net worth?
Lipocine Inc. has a market value (market cap) of $13M at the latest share price, and shareholders' equity of $21.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Lipocine Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $11.9M on revenue of $1.6M.
How much revenue does Lipocine Inc. make?
Over the twelve months to June 30, 2026 Lipocine Inc. reported revenue of $1.6M.
When did Lipocine Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 1, 2026.
When is Lipocine Inc.'s next earnings report?
Lipocine Inc.'s next report was expected around October 16, 2026 and is not on file with the SEC yet.
Similar companies
Compare LPCN with
Follow LPCN
Get an email when Lipocine Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Lipocine Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.